Kodiak Sciences: When Clinical Progress Stops Excusing the Cash Burn Rate

Kodiak Sciences Inc (NASDAQ: KOD) reports first-quarter 2026 earnings on April 2, 2026, with the market focused on whether the clinical-stage biopharma can sustain momentum following positive Phase 3 GLOW2 results for its lead candidate Zenkuda (tarcocimab tedromer) in diabetic retinopathy. The central question is whether management can articulate a clear path to its multi-indication Biologics License Application (BLA) submission while advancing its diversified pipeline of bispecific antibody candidates targeting retinal diseases.

Part 1: Earnings Preview

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases using its proprietary Antibody Biopolymer Conjugate (ABC) platform, with lead candidates including Zenkuda (tarcocimab tedromer) and KSI-501 for conditions such as diabetic retinopathy and wet age-related macular degeneration (AMD). The company has no product revenue and is advancing multiple late-stage programs that could define its commercial future.

Kodiak reports first-quarter 2026 results before the market opens on April 2, 2026. Analysts expect a loss of $0.86 per share on no revenue, with estimates ranging from a loss of $0.64 to $1.07. The most recently reported quarter (Q4 2025) delivered a loss of $1.04 per share, missing the consensus estimate of $1.02 by two cents. Year-over-year, the Q1 2026 estimate of a $0.86 loss represents a 21.10% improvement compared to the $1.09 loss reported in Q1 2025, reflecting analyst expectations for narrowing losses as the company advances its clinical programs.

Three key themes define this earnings story:

GLOW2 Phase 3 Success and BLA Timeline: The positive topline results from the GLOW2 study showing meaningful efficacy, safety, and durability of Zenkuda in diabetic retinopathy represent a significant validation of Kodiak's ABC platform. Investors will be listening for management's accelerated timeline toward a multi-indication BLA submission and any regulatory pathway updates that could bring the company closer to commercialization.

DAYBREAK Study Enrollment and September Data Readout: Kodiak completed enrollment in the Phase 3 DAYBREAK study of both Zenkuda and KSI-501 in wet AMD patients, with approximately 690 subjects enrolled and topline data expected in September 2026. This dual-candidate approach in a large market opportunity could differentiate Kodiak's commercial strategy, and investors will want clarity on study progress and data expectations.

Pipeline Expansion Beyond Anti-VEGF: The company is rapidly advancing KSI-101 with enrollment progressing in the Phase 3 PEAK and PINNACLE studies (topline results expected in Q4 2026 and Q2 2027, respectively), while also developing bispecific antibody candidates KSI-102 and KSI-103 targeting inflammatory pathways. The Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation showed compelling results with rapid vision improvements and sustained retinal drying, highlighting the breadth of Kodiak's platform beyond anti-VEGF therapies into inflammatory retinal diseases.

Analyst commentary ahead of the release has been notably bullish. UBS initiated coverage in January 2026 with a Buy rating and $50 price target, while HC Wainwright raised its target to $38 from $26 in February 2026, citing the strength of the clinical data and the company's diversified pipeline approach. Multiple analysts have emphasized that after twenty years of anti-VEGF therapy, retinal commercial franchises continue to drive major revenue for large pharma companies, validating both the market opportunity and the persistent unmet need that Kodiak's differentiated molecules could address.

Part 2: Historical Earnings Performance

Kodiak Sciences has consistently missed earnings estimates over the past four quarters, though the magnitude of misses has generally been modest. In Q1 2025, the company reported a loss of $1.09 per share versus the $0.89 estimate, a 22.47% miss that represented the largest deviation in the recent period. The subsequent three quarters showed tighter misses: Q2 2025 came in at a $1.03 loss versus $1.01 expected (1.98% miss), Q3 2025 delivered a $1.16 loss versus $1.07 expected (8.41% miss), and most recently Q4 2025 reported a $1.04 loss versus $1.02 expected (1.96% miss).

The pattern reveals a company that has struggled to meet even modest expectations for loss reduction, though the sequential improvement in miss magnitude from Q1 2025's 22.47% to Q4 2025's 1.96% suggests management may be gaining better visibility into operating expenses as clinical programs mature. The Q4 2025 result of $1.04 per share loss was actually better than the prior year's Q4 2024 loss of $1.13, indicating year-over-year progress in narrowing losses despite the consistent pattern of missing quarterly estimates. With analysts projecting a $0.86 loss for Q1 2026—representing 21.10% improvement versus the $1.09 loss in Q1 2025—investors will be watching whether Kodiak can finally meet or beat expectations while demonstrating the operating leverage from its advancing clinical pipeline.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Kodiak Sciences typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Kodiak's post-earnings price behavior has been volatile and unpredictable, with an average absolute Day 0 move of 6.27% and Day +1 move of 7.69%. The most dramatic reaction came after the March 2024 report, when the stock plunged 29.40% on Day 0 followed by another 15.40% decline on Day +1, reflecting severe disappointment with results. More recently, the pattern has moderated significantly—the November 2025 report saw a 6.81% Day 0 decline followed by a 3.39% Day +1 gain, while the August 2025 report showed minimal Day 0 movement (1.17% gain) but a substantial 16.47% Day +1 surge.

The wide Day 0 trading ranges averaging 9.51% and Day +1 ranges averaging 14.42% underscore the stock's tendency for intraday volatility around earnings events. Investors should prepare for significant two-day price swings, with historical data suggesting the Day +1 session often delivers larger moves than the initial reaction as the market digests clinical pipeline updates and management commentary. The recent trend toward more muted Day 0 reactions followed by stronger Day +1 moves suggests the market may be taking more time to evaluate the company's complex clinical development story rather than reacting immediately to headline EPS figures.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 14.97% through the April 17 monthly expiration, which is substantially higher than the average historical Day 0 move of 6.27% but roughly in line with the average Day +1 move of 7.69%. This elevated implied volatility of 100.55% suggests options traders are anticipating significant post-earnings movement, potentially reflecting uncertainty around management's BLA timeline commentary and clinical program updates that could materially impact the company's valuation.

Part 3: What Analysts Are Saying

Kodiak Sciences carries a Moderate Buy consensus rating from analysts, with the current average recommendation of 3.89 unchanged over the past month. The breakdown shows 5 Strong Buy ratings, 3 Hold ratings, and 1 Strong Sell rating among the 9 analysts covering the stock, reflecting generally positive sentiment tempered by some caution about execution risk and the company's cash runway.

The average price target of $46.71 implies 9.1% upside from the current price of $42.81, though the wide range of targets—from a low of $14.00 to a high of $80.00—reveals significant disagreement about Kodiak's ultimate value. The $80 high target from UBS, which initiated coverage in January 2026, reflects bullish conviction in the company's ABC platform and multi-indication commercial potential, while the $14 low target suggests some analysts remain skeptical about the company's ability to successfully navigate regulatory pathways and achieve commercialization.

Analyst sentiment has remained unchanged over the past month according to the precomputed trend indicator, suggesting the recent positive clinical data from GLOW2 and pipeline progress updates were largely anticipated by the Street. The concentration of Strong Buy ratings (5 out of 9 analysts) indicates that leading research firms see meaningful value in Kodiak's differentiated approach to retinal diseases, particularly as the company moves closer to potential BLA submissions that could transform it from a clinical-stage story into a commercial-stage biotech with significant revenue potential in large, established markets.

Part 4: Technical Picture

Kodiak Sciences enters earnings with exceptionally strong technical momentum, as reflected in the Barchart Technical Opinion showing a 100% Buy signal—a dramatic strengthening from 24% Buy just one week ago and 88% Buy one month ago. This maximum bullish reading indicates the stock has broken out to new technical highs with powerful momentum across all timeframes.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates explosive near-term momentum as the stock surges into earnings
• Medium-term (100% Buy): Strongest possible reading confirms the intermediate-term trend has turned decisively bullish
• Long-term (100% Buy): Maximum buy signal across the longest timeframe suggests a major trend reversal is underway

Trend Characteristics: The opinion strength is rated as Maximum with direction in the Top 1%, indicating Kodiak is exhibiting one of the strongest technical setups in the entire market heading into this earnings release—a rare configuration that suggests powerful institutional accumulation and momentum that could amplify any positive earnings reaction.

The stock is trading at $42.81, well above all key moving averages and showing a clean uptrend structure. The price is above the 5-day moving average of $38.27, above the 10-day of $30.31, above the 20-day of $27.24, above the 50-day of $25.92, above the 100-day of $25.07, and above the 200-day of $17.59. This alignment with all moving averages sloping upward represents a textbook bullish configuration, with each shorter-term average above each longer-term average—a pattern technical analysts call a "golden ladder" that typically precedes sustained uptrends.

The recent surge from the $38.27 level (5-day moving average) to current levels above $42 represents a powerful breakout that has likely triggered momentum-following algorithms and attracted growth-oriented institutional buyers. The 200-day moving average at $17.59 provides perspective on the magnitude of this rally—the stock has more than doubled from that long-term trend line, reflecting a fundamental re-rating of the company's prospects following the positive GLOW2 data and pipeline progress. However, the parabolic nature of the recent advance and the stock's position well above all moving averages creates a technically extended setup where any disappointment on the earnings call could trigger sharp profit-taking, particularly given the options market's expectation of a 14.97% move. The overall technical picture is extraordinarily supportive heading into earnings, but the lack of nearby support levels means volatility could be amplified in either direction.